Cargando…

The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia

INTRODUCTION: Timely diagnosis of invasive candidiasis (IC) remains difficult as the clinical presentation is not specific and blood cultures lack sensitivity and need a long incubation time. Thus, non-culture-based methods for diagnosing IC have been developed. Mannan antigen (Mn) and anti-mannan a...

Descripción completa

Detalles Bibliográficos
Autores principales: Mikulska, Małgorzata, Calandra, Thierry, Sanguinetti, Maurizio, Poulain, Daniel, Viscoli, Claudio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219989/
https://www.ncbi.nlm.nih.gov/pubmed/21143834
http://dx.doi.org/10.1186/cc9365
_version_ 1782216925451911168
author Mikulska, Małgorzata
Calandra, Thierry
Sanguinetti, Maurizio
Poulain, Daniel
Viscoli, Claudio
author_facet Mikulska, Małgorzata
Calandra, Thierry
Sanguinetti, Maurizio
Poulain, Daniel
Viscoli, Claudio
author_sort Mikulska, Małgorzata
collection PubMed
description INTRODUCTION: Timely diagnosis of invasive candidiasis (IC) remains difficult as the clinical presentation is not specific and blood cultures lack sensitivity and need a long incubation time. Thus, non-culture-based methods for diagnosing IC have been developed. Mannan antigen (Mn) and anti-mannan antibodies (A-Mn) are present in patients with IC. On behalf of the Third European Conference on Infections in Leukemia, the performance of these tests was analysed and reviewed. METHODS: The literature was searched for studies using the commercially available sandwich enzyme-linked immunosorbent assays (Platelia™, Bio-Rad Laboratories, Marnes-la-Coquette, France) for detecting Mn and A-Mn in serum. The target condition of this review was IC defined according to 2008 European Organization for Research and Treatment of Cancer/Mycoses Study Group criteria. Sensitivity, specificity and diagnostic odds ratios (DOR) were calculated for Mn, A-Mn and combined Mn/A-Mn testing. RESULTS: Overall, 14 studies that comprised 453 patients and 767 controls were reviewed. The patient populations included in the studies were mainly haematological and cancer cases in seven studies and mainly intensive care unit and surgery cases in the other seven studies. All studies but one were retrospective in design. Mn sensitivity was 58% (95% confidence interval [CI], 53-62); specificity, 93% (95% CI, 91-94) and DOR, 18 (95% CI 12-28). A-Mn sensitivity was 59% (95% CI, 54-65); specificity, 83% (95% CI, 79-97) and DOR, 12 (95% CI 7-21). Combined Mn/A-Mn sensitivity was 83% (95% CI, 79-87); specificity, 86% (95% CI, 82-90) and DOR, 58 (95% CI 27-122). Significant heterogeneity of the studies was detected. The sensitivity of both Mn and A-Mn varied for different Candida species, and it was the highest for C. albicans, followed by C. glabrata and C. tropicalis. In 73% of 45 patients with candidemia, at least one of the serological tests was positive before the culture results, with mean time advantage being 6 days for Mn and 7 days for A-Mn. In 21 patients with hepatosplenic IC, 18 (86%) had Mn or A-Mn positive test results at a median of 16 days before radiological detection of liver or spleen lesions. CONCLUSIONS: Mn and A-Mn are useful for diagnosis of IC. The performance of combined Mn/A-Mn testing is superior to either Mn or A-Mn testing.
format Online
Article
Text
id pubmed-3219989
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32199892011-11-18 The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia Mikulska, Małgorzata Calandra, Thierry Sanguinetti, Maurizio Poulain, Daniel Viscoli, Claudio Crit Care Research INTRODUCTION: Timely diagnosis of invasive candidiasis (IC) remains difficult as the clinical presentation is not specific and blood cultures lack sensitivity and need a long incubation time. Thus, non-culture-based methods for diagnosing IC have been developed. Mannan antigen (Mn) and anti-mannan antibodies (A-Mn) are present in patients with IC. On behalf of the Third European Conference on Infections in Leukemia, the performance of these tests was analysed and reviewed. METHODS: The literature was searched for studies using the commercially available sandwich enzyme-linked immunosorbent assays (Platelia™, Bio-Rad Laboratories, Marnes-la-Coquette, France) for detecting Mn and A-Mn in serum. The target condition of this review was IC defined according to 2008 European Organization for Research and Treatment of Cancer/Mycoses Study Group criteria. Sensitivity, specificity and diagnostic odds ratios (DOR) were calculated for Mn, A-Mn and combined Mn/A-Mn testing. RESULTS: Overall, 14 studies that comprised 453 patients and 767 controls were reviewed. The patient populations included in the studies were mainly haematological and cancer cases in seven studies and mainly intensive care unit and surgery cases in the other seven studies. All studies but one were retrospective in design. Mn sensitivity was 58% (95% confidence interval [CI], 53-62); specificity, 93% (95% CI, 91-94) and DOR, 18 (95% CI 12-28). A-Mn sensitivity was 59% (95% CI, 54-65); specificity, 83% (95% CI, 79-97) and DOR, 12 (95% CI 7-21). Combined Mn/A-Mn sensitivity was 83% (95% CI, 79-87); specificity, 86% (95% CI, 82-90) and DOR, 58 (95% CI 27-122). Significant heterogeneity of the studies was detected. The sensitivity of both Mn and A-Mn varied for different Candida species, and it was the highest for C. albicans, followed by C. glabrata and C. tropicalis. In 73% of 45 patients with candidemia, at least one of the serological tests was positive before the culture results, with mean time advantage being 6 days for Mn and 7 days for A-Mn. In 21 patients with hepatosplenic IC, 18 (86%) had Mn or A-Mn positive test results at a median of 16 days before radiological detection of liver or spleen lesions. CONCLUSIONS: Mn and A-Mn are useful for diagnosis of IC. The performance of combined Mn/A-Mn testing is superior to either Mn or A-Mn testing. BioMed Central 2010 2010-12-08 /pmc/articles/PMC3219989/ /pubmed/21143834 http://dx.doi.org/10.1186/cc9365 Text en Copyright ©2010 Mikulska et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (<url>http://creativecommons.org/licenses/by/2.0</url>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Mikulska, Małgorzata
Calandra, Thierry
Sanguinetti, Maurizio
Poulain, Daniel
Viscoli, Claudio
The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia
title The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia
title_full The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia
title_fullStr The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia
title_full_unstemmed The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia
title_short The use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the Third European Conference on Infections in Leukemia
title_sort use of mannan antigen and anti-mannan antibodies in the diagnosis of invasive candidiasis: recommendations from the third european conference on infections in leukemia
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219989/
https://www.ncbi.nlm.nih.gov/pubmed/21143834
http://dx.doi.org/10.1186/cc9365
work_keys_str_mv AT mikulskamałgorzata theuseofmannanantigenandantimannanantibodiesinthediagnosisofinvasivecandidiasisrecommendationsfromthethirdeuropeanconferenceoninfectionsinleukemia
AT calandrathierry theuseofmannanantigenandantimannanantibodiesinthediagnosisofinvasivecandidiasisrecommendationsfromthethirdeuropeanconferenceoninfectionsinleukemia
AT sanguinettimaurizio theuseofmannanantigenandantimannanantibodiesinthediagnosisofinvasivecandidiasisrecommendationsfromthethirdeuropeanconferenceoninfectionsinleukemia
AT poulaindaniel theuseofmannanantigenandantimannanantibodiesinthediagnosisofinvasivecandidiasisrecommendationsfromthethirdeuropeanconferenceoninfectionsinleukemia
AT viscoliclaudio theuseofmannanantigenandantimannanantibodiesinthediagnosisofinvasivecandidiasisrecommendationsfromthethirdeuropeanconferenceoninfectionsinleukemia
AT mikulskamałgorzata useofmannanantigenandantimannanantibodiesinthediagnosisofinvasivecandidiasisrecommendationsfromthethirdeuropeanconferenceoninfectionsinleukemia
AT calandrathierry useofmannanantigenandantimannanantibodiesinthediagnosisofinvasivecandidiasisrecommendationsfromthethirdeuropeanconferenceoninfectionsinleukemia
AT sanguinettimaurizio useofmannanantigenandantimannanantibodiesinthediagnosisofinvasivecandidiasisrecommendationsfromthethirdeuropeanconferenceoninfectionsinleukemia
AT poulaindaniel useofmannanantigenandantimannanantibodiesinthediagnosisofinvasivecandidiasisrecommendationsfromthethirdeuropeanconferenceoninfectionsinleukemia
AT viscoliclaudio useofmannanantigenandantimannanantibodiesinthediagnosisofinvasivecandidiasisrecommendationsfromthethirdeuropeanconferenceoninfectionsinleukemia